-
06
2023
Caliway Announces Positive Data from CBL-0201EFP Phase 2-Stage 1 Study of CBL-514 in Treating Moderate to Severe Cellulite
The highest dose of CBL-514 treatment demonstrated the best efficacy, 87.5% of thighs achieved at least 1-level improvement in cellulite severity two weeks after CBL-514 treatment.
-
05
2023
Caliway Biopharmaceuticals Announces Initiation of Subject Recruitment in CBL-0204 Phase 2b Study Evaluating the Efficacy of CBL-514 in Abdominal Subcutaneous Fat Reduction
The study is expected to complete in Q2 2024, and the topline results are anticipated in Q3 2024.
-
05
2023
Caliway Has Been Featured In Clinical Trial Arena Pipeline Moves
Clinical Trial Arena: May 2nd Pipeline Moves - Completion of Phase IIa non-malignant disorder trial
-
04
2023
Caliway Biopharmaceuticals Announces Initiation of Subject Recruitment in a Phase 2-Stage 2 Study Evaluating the Efficacy of CBL-514 in Treating Moderate to Severe Cellulite
The subject recruitment and treatment in CBL-0201EFP Phase 2-Stage 1 is completed.
-
08
2022
Caliway Announces Achievements in Revolutionary Fat Reduction Therapy
CBL-514 has demonstrated promising clinical effectiveness and safety in reducing local fat through a mechanism of adipocytes apoptosis.
-
04
2022
FDA grants IND approval for phase II for treating rare diseases
CBL-514 injection is suitable for treating rare diseases- Dercum's disease. Applications for U.S. Phase II IND was approved. Upcoming IPO in 2022.
-
08
2021
Caliway awarded patents for CBL-514 in the major market countries
CBL-514 has obtained more than 30 patents in major markets, including the United States, Europe, Canada, Australia, Taiwan, South Korea, Singapore, Russia and Mexico, etc.